Who are placebo + Rosuvastatin's main competitors?

Direct comparators (same drug class / molecular target / therapeutic area): Crestor, Lipitor, Lescol, FLUVASTATIN SODIUM, Amlodipine, Telmisartan, Amiloride Compound , Simvastatin, sirolimus, mycophenolat mofetil, fluvastatin.

How often does this brief refresh?

Every 30 minutes from primary sources (FDA, EMA, MHRA, PMDA, ClinicalTrials.gov, USPTO). Subscribe to the RSS feed below for push alerts.

How do I get this as a recurring report?

Subscribe to /feed/ci/placebo-rosuvastatin.xml in any RSS reader (Feedly, Inoreader, NewsBlur). Every regulatory action, trial readout, or patent event lands in your feed automatically.

Last reviewed 2026-05-17 · How we verify

placebo + Rosuvastatin — Competitive Intelligence Brief

Name: Drug Landscape Pharmaceutical Database
Creator: Drug Landscape
Published: 2026-01-01
License: https://creativecommons.org/licenses/by/4.0/

placebo + Rosuvastatin (placebo + Rosuvastatin) competitive landscape: 6 comparators, recent regulatory actions, upcoming PDUFA, patent timeline. Class: HMG-CoA reductase inhibitor. Area: Cardiovascular.

phase 3 HMG-CoA reductase inhibitor HMG-CoA reductase Cardiovascular Small molecule Live · refreshed every 30 min

Target snapshot

placebo + Rosuvastatin (placebo + Rosuvastatin) — Jeil Pharmaceutical Co., Ltd.. Rosuvastatin inhibits HMG-CoA reductase, a key enzyme in the cholesterol biosynthesis pathway.

Comparator set (6 drugs)

Auto-detected by same drug class / molecular target / therapeutic area, ranked by phase + recency. Override with ?vs=slug1,slug2,….

Drug	Generic	Sponsor	Phase	Class	Target	Approval / PDUFA
placebo + Rosuvastatin TARGET	placebo + Rosuvastatin	Jeil Pharmaceutical Co., Ltd.	phase 3	HMG-CoA reductase inhibitor	HMG-CoA reductase
Crestor	rosuvastatin	AstraZeneca	marketed	HMG-CoA reductase inhibitor (statin)	HMG-CoA reductase	2003-01-01
Lipitor	atorvastatin	Pfizer Inc.	marketed	HMG-CoA reductase inhibitor (statin)	HMG-CoA reductase	1996-12-17
Lescol	FLUVASTATIN	Novartis	marketed	HMG-CoA Reductase Inhibitor	HMG-CoA reductase	1993-01-01
FLUVASTATIN SODIUM	FLUVASTATIN SODIUM		marketed		HMG-CoA reductase	1993-01-01
Amlodipine, Telmisartan, Amiloride Compound , Simvastatin	Amlodipine, Telmisartan, Amiloride Compound , Simvastatin	Chinese Academy of Medical Sciences, Fuwai Hospital	marketed	Antihypertensive combination (calcium channel blocker + angiotensin II receptor blocker + potassium-sparing diuretic + statin)	L-type calcium channels, AT1 angiotensin II receptor, epithelial sodium channels (ENaC), HMG-CoA reductase
sirolimus, mycophenolat mofetil, fluvastatin	sirolimus, mycophenolat mofetil, fluvastatin	University Hospital Schleswig-Holstein	marketed	Immunosuppressive combination therapy with statin	mTOR, IMPDH, HMG-CoA reductase

Recent regulatory actions (last 90 days)

No regulatory actions in the last 90 days for this set.

Upcoming PDUFA dates (next 180 days)

No PDUFA dates in the next 180 days for this set.

Patent timeline (forward window)

2037-06-07 — Lipitor · 11654106 · US
2037-06-07 — Lipitor · 11369567 · US

Sponsor landscape (HMG-CoA reductase inhibitor class)

Beijing Anzhen Hospital · 1 drug in this class
Boryung Pharmaceutical Co., Ltd · 1 drug in this class
Jeil Pharmaceutical Co., Ltd. · 1 drug in this class
National Heart, Lung, and Blood Institute (NHLBI) · 1 drug in this class

Subscribe to ongoing alerts

Push every new event for this competitive set into your RSS reader, IFTTT/Zapier workflow, or email digest:

Cite this brief

Drug Landscape (2026). placebo + Rosuvastatin — Competitive Intelligence Brief. https://druglandscape.com/ci/placebo-rosuvastatin. Accessed 2026-05-17.

Build your own brief

Pick any drug + add comparators:

https://druglandscape.com/ci/{slug} — auto-detected competitors
https://druglandscape.com/ci/{slug}?vs=drug1,drug2,drug3 — explicit comparators
Brand names auto-resolve: /ci/keytruda → 301 → /ci/pembrolizumab